Tamoxifen or Cyproterone Acetate in Combination with Buserelin Are Ineffective in Patients with Pancreatic Adenocarcinoma
B. Swarovsky;M. Wolf;K. Havemann;R. Arnold;
oncology1993Vol. 50pp. 226-229
194
swarovsky1993oncologytamoxifen
Abstract
Experimental evidence and preliminary clinical data suggest a responsiveness of pancreatic adenocarcinoma to sex hormones and LH-RH agonists. In this study, we investigated the effect of the antiestrogen tamoxifen and the anti-androgen cyproterone acetate in combination with the LH-RH agonist buserelin in 9 patients with unresectable pancreatic ade